<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Prasad A. Thakurdesai</style></author><author><style face="normal" font="default" size="100%">Pallavi O. Deshpande</style></author><author><style face="normal" font="default" size="100%">Mukul P. Pore</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Characterization, Preclinical Efficacy and Toxicity Evaluations of Flavonoids Glycosides based Standardized Fenugreek Seed Extract (FEFLG)</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Acute toxicity</style></keyword><keyword><style  face="normal" font="default" size="100%">CD38+ enzyme inhibition</style></keyword><keyword><style  face="normal" font="default" size="100%">Chromosomal aberration.</style></keyword><keyword><style  face="normal" font="default" size="100%">Fenugreek seeds</style></keyword><keyword><style  face="normal" font="default" size="100%">Flavonoid glycosides</style></keyword><keyword><style  face="normal" font="default" size="100%">Mutagenicity</style></keyword><keyword><style  face="normal" font="default" size="100%">Subchronic Toxicity</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">March 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">90-105</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Fenugreek seeds, a natural food chain raw material, is known to have many flavonoid glycosides. &lt;strong&gt;Objective:&lt;/strong&gt; Characterization, preclinical efficacy, and safety evaluation of flavonoid glycosidebased standardized fenugreek seed extract (FEFLG). &lt;strong&gt;Methods:&lt;/strong&gt; FEFLG was characterized for a group of flavonoid glycoside marker compounds by HPLC. The CD38+ enzyme inhibition efficacy was assessed &lt;em&gt;in vitro.&lt;/em&gt; In addition, acute oral toxicity (AOT) and subchronic, 90-day repeated-dose oral toxicity (&lt;em&gt;in vivo&lt;/em&gt;), mutagenicity (AMES test, &lt;em&gt;in vitro&lt;/em&gt;) and chromosome aberration test (&lt;em&gt;in vitro&lt;/em&gt;) of FEFLG were evaluated. &lt;strong&gt;Results&lt;/strong&gt;: The FEFLG was found to have 49.85% of total flavonoid glycosides content in FEFLG (25.15% of Group 1: vitexin, isovitexin and vitexin 2-o- rhamnoside and 24.70% of Group 2 (vicenin derivatives, schaftoside, iso-schaftoside, orientin and iso-orientin). FEFLG showed CD38+ enzyme inhibition&lt;em&gt; in vitro&lt;/em&gt; (IC50= 0.96 μg/ml) equivalent to the positive control, apigenin. FEFLG did not show any toxicity at an acute oral dose of more than 2000 mg/kg (median lethal dose, LD50) with a limit dose of 5000 mg/kg. The 90-day repeated-dose oral administration of FEFLG did not induce significant toxicological changes till the maximum dose of 1000 mg/kg in male and female rats, indicating no observed adverse effect level, NOAEL ≥ 1000 mg/kg. FEFLG did not show mutagenicity (up to a concentration of 5000 μg/plate) or structural chromosomal aberrations (up to 5000 μg /ml). &lt;strong&gt;Conclusion:&lt;/strong&gt; The CD38+ enzyme inhibitor efficacy&lt;em&gt; in vitro&lt;/em&gt;, oral safety &lt;em&gt;in vivo&lt;/em&gt; and absence of mutagenicity or genotoxicity of FEFLG indicated its potential for anti-aging applications.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">1</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">90</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Prasad A. Thakurdesai*, Pallavi O. Deshpande, Mukul P. Pore&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;Indus Biotech Limited, Pune, INDIA.&lt;/p&gt;
</style></auth-address></record></records></xml>